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Introduction 
o Bacteriophage (phage) are obligate intracellular 
parasites that multiply inside bacteria by making use 
of some or all of the host biosynthetic machinery 
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Introduction 
o There are many similarities between 
bacteriophages and animal cell 
viruses. Thus, bacteriophage can 
be viewed as model systems for 
animal cell viruses. In addition a 
knowledge of the life cycle of 
bacteriophage is necessary to 
understand one of the mechanisms 
by which bacterial genes can be 
transferred from one bacterium to 
another. 
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Introduction 
o Bacteriophage are used in the diagnostic laboratory 
for the identification of pathogenic bacteria (phage 
typing) 
 
 
 
 
 
 
 
By:Peyman Hosseini / Dr.M.Aslanimehr 
4 
Introduction 
o phage typing is not used in the routine clinical 
laboratory, it is used in reference laboratories for 
epidemiological purposes 
o Recently, new interest has developed in the possible 
use of bacteriophage for treatment of bacterial 
infections and in prophylaxis 
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STRUCTURE OF BACTERIOPHAGE 
 
  Structure 
o Bacteriophage come in     
many different sizes and 
shapes 
o 1. Size - T4 is among the 
largest phages; it is 
approximately 200 nm long 
and 80-100 nm wide. Other 
phages are smaller. Most 
phages range in size from 
24-200 nm in length 
 
The basic structural features of 
bacteriophages  
depicts the phage called T4 
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STRUCTURE OF BACTERIOPHAGE 
o 2. Head or Capsid - All 
phages contain a head 
structure which can vary 
in size and shape. Some 
are icosahedral (20 sides) 
others are filamentous. 
The head or capsid is 
composed of many 
copies of one or more 
different proteins. Inside 
the head is found the 
nucleic acid. The head 
acts as the protective 
covering for the nucleic 
acid. 
 
 
3. Tail - Many but not all 
phages have tails 
attached to the phage 
head.The tail is a hollow 
tub  through which the 
nucleic acid pa ses 
during infection. In the 
more complex phages 
like T4 the tail is 
surrounded by a 
contractile sheath which 
ntracts during 
infection of the 
bacterium 
At the end of the tail the 
more compl x phages 
like T4 have a base plate 
and one or more tai  
fibers attached to it. The 
base plate and tail fibers 
are involv d in the
binding of th  phage to 
th bact ri l cell 
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INFECTION OF HOST CELLS 
 A. Adsorption 
o The first step in the infection process is the adsorption of 
the phage to the bacterial cell. This step is mediated by 
the tail fibers or by some analogous structure on those 
phages that lack tail fibers and it is reversible 
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INFECTION OF HOST CELLS 
o The tail fibers attach to specific receptors on the 
bacterial cell. The nature of the bacterial receptor 
varies for different bacteria 
o Examples include proteins on the outer surface of the 
bacterium, LPS, pili, and lipoprotein. These receptors 
are on the bacteria for other purposes and phage 
have evolved to use these receptors for infection 
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INFECTION OF HOST CELLS 
 B. Irreversible attachment 
o The attachment of the 
phage to the bacterium 
via the tail fibers is a weak 
and is reversible. 
Irreversible binding of 
phage to a bacterium is 
mediated by one or more 
of the components of the 
base plate. Phages 
lacking base plates have 
other ways of becoming 
tightly bound to the 
bacterial cell 
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INFECTION OF HOST CELLS 
 C. Sheath Contraction 
o The irreversible binding of 
the phage to the 
bacterium results in the 
contraction of the sheath 
and the hollow tail fiber is 
pushed through the 
bacterial envelope 
o Phages that don't have contractile sheaths use other 
mechanisms to get the phage particle through the 
bacterial envelope. Some phages have enzymes that 
digest various components of the bacterial envelope 
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INFECTION OF HOST CELLS 
 D. Nucleic Acid Injection 
o When the phage has gotten 
through the bacterial 
envelope the nucleic acid 
from the head passes through 
the hollow tail and enters the 
bacterial cell. Usually, the only 
phage component that 
actually enters the cell is the 
nucleic acid.  
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INFECTION OF HOST CELLS 
o The remainder of the phage remains on the outside of 
the bacterium. There are some exceptions to this rule. 
This is different from animal cell viruses in which most of 
the virus particle usually gets into the cell. This 
difference is probably due to the inability of bacteria 
to engulf materials. 
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PHAGE MULTIPLICATION 
CYCLE 
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PHAGE MULTIPLICATION 
CYCLE 
 A. Lytic or Virulent Phages 
o 1. Definition 
Lytic or virulent phages are phages which can only 
multiply on bacteria and kill the cell by lysis at the end of 
the life cycle 
o 2. Life cycle 
o a. Eclipse period  
During the eclipse phase, no infectious phage particles 
can be found either inside or outside the bacterial cell. 
The phage nucleic acid takes over the host biosynthetic 
machinery and phage specified     m-RNA's and proteins 
are made. There is an orderly expression of phage 
directed macromolecular synthesis, just as one sees in 
animal virus infections 
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PHAGE MULTIPLICATION 
CYCLE 
o Early m-RNA's code for early proteins which are 
needed for phage DNA synthesis and for shutting off 
host DNA, RNA and protein biosynthesis. In some cases 
the early proteins actually degrade the host 
chromosome. After phage DNA is made late m-RNA's 
and late proteins are made. The late proteins are the 
structural proteins that comprise the phage as well as 
the proteins needed for lysis of the bacterial cell 
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PHAGE MULTIPLICATION 
CYCLE 
o b. Intracellular Accumulation Phase 
In this phase the nucleic acid and structural proteins 
that have been made are assembled and infectious 
phage particles accumulate within the cell. 
o c. Lysis and Release Phase  
After a while the bacteria begin to lyse due to the 
accumulation of the phage lysis protein and 
intracellular phage are released into the medium. The 
number of particles released per infected bacteria 
may be as high as 1000 
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PHAGE MULTIPLICATION 
CYCLE 
 Assay for Lytic Phage 
o Plaque assay  
Lytic phage are enumerated by a plaque assay. A 
plaque is a clear area which results from the lysis of 
bacteria (Figure 4). Each plaque arises from a single 
infectious phage. The infectious particle that gives rise 
to a plaque is called a PFU (Plaque Forming Unit) 
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PHAGE MULTIPLICATION 
CYCLE 
 B. Lysogenic or Temperate Phage 
o Definition  
Lysogenic or temperate phages are those that can 
either multiply via the lytic cycle or enter a quiescent 
state in the cell. In this quiescent state most of the 
phage genes are not transcribed; the phage genome 
exists in a repressed state. The phage DNA in this 
repressed state is called a prophage because it is not 
a phage but it has the potential to produce phage 
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PHAGE MULTIPLICATION 
CYCLE 
o In most cases the phage DNA actually integrates 
into the host chromosome and is replicated along 
with the host chromosome and passed on to the 
daughter cells. The cell harboring a prophage is not 
adversely affected by the presence of the 
prophage and the lysogenic state may persist 
indefinitely. The cell harboring a prophage is termed 
a lysogen 
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PHAGE MULTIPLICATION 
CYCLE 
 Events Leading to Termination of Lysogeny 
o Anytime a lysogenic bacterium is exposed to 
adverse conditions, the lysogenic state can be 
terminated. This process is called induction. 
Conditions which favor the termination of the 
lysogenic state include: desiccation, exposure to 
UV or ionizing radiation, exposure to mutagenic 
chemicals, etc. Adverse conditions lead to the 
production of proteases (rec A protein) which 
destroy the repressor protein. This in turn leads to the 
expression of the phage genes, reversal of the 
integration process and lytic multiplication. 
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PHAGE MULTIPLICATION 
CYCLE 
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PHAGE MULTIPLICATION 
CYCLE 
 Lytic vs Lysogenic Cycle 
o The decision for lambda to enter the lytic or lysogenic 
cycle when it first enters a cell is determined by the 
concentration of the repressor and another phage 
protein called cro in the cell. The cro protein turns off 
the synthesis of the repressor and thus prevents the 
establishment of lysogeny. Environmental conditions 
that favor the production of cro will lead to the lytic 
cycle while those that favor the production of the 
repressor will favor lysogeny. 
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Phage therapy 
 Bacteriophages were discovered by two people: 
the English bacteriologist 
Frederick Twort in 1915  
the French-Canadian microbiologist 
Felix d’Herelle in 1917 
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Phage therapy 
 Immediately after their discovery, the thought of using 
phages to fight bacterial infections was already 
apparent 
 D’Herelle began testing the therapeutic effects that 
phages may have on chickens and cows first and the 
tests were successful 
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Phage therapy 
 human tests were conducted and the development 
of phage therapy became more extensive especially 
with the foundation of the Eliavia Institute in 1923 
 
The George Eliava Institute of 
Bacteriophage, Microbiology and 
Virology, has been active since the 
1930s in the field of phage therapy 
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Phage therapy 
 the pharmaceutical 
company Eli Lilly began the 
commercialization of phage 
therapy in the US during the 
1940s 
 
 During the Second World 
War, phages were used to 
treat bacterial diseases 
among soldiers of the Soviet 
Union, particularly gangrene 
and dysentery 
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Phage therapy 
 The development of 
antibiotics in the 1950s led to 
a temporary setback on 
phage therapy as the use of 
antibiotics became more 
favourable. However, there 
has been a renewed 
interest in the development 
and employment of phage 
therapy in more 
applications 
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Delivery to targeted bacteria 
 
 When phages were first discovered and applied in a 
clinical setting for the treatment of diseases, they were 
injected in the vicinity of the infection 
 
Venous leg ulcers infected with drug-resistant 
Pseudomonas and treated with bacteriophages over 5 
months 
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Delivery to targeted bacteria 
 Later mechanisms of delivery included 
o topical administration 3 times a day, 
o eye drops 
o orally before meals 
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Delivery to targeted bacteria 
 Phages, unlike many antibiotic molecules, are not 
diffusible across membranes and must therefore have 
a method of delivery to the target cells 
o the best delivery mechanism may lie in using other 
nonpathogenic species of bacteria to bring the 
phage to its pathogenic target 
 
The effect of treatment 
of Mycobacterium avium infected 
macrophages with Mycobacterium 
smegmatis 48 hours after infection 
(with and without the TM4 lytic phage) 
on number of intracellular M. avium 
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Delivery to targeted bacteria 
 Some researchers have categorized different delivery 
modes as 'passive' and 'active‘ 
o Passive delivery is achieved by administering large 
doses of phage that likely exceed how many bacteria 
are present 
o Active delivery, on the other hand, involves making 
sure that the phage lives long enough to generate 
progeny cells which will then kill the bacterial cells 
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Medical Uses  
 Not long after his 
discovery, d'Herelle 
used phages to treat 
dysentery 
 the first reported 
application of phages 
to treat infectious 
diseases of humans 
came from Bruynoghe 
and Maisin in France 
in 1921. They used 
phages to treat 
staphylococcal skin 
disease 
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Medical Uses  
 d'Herelle used various phage preparations to treat 
thousands of patients having cholera and/or bubonic 
plague in India 
 As late as the 1940s, Eli Lilly was producing seven 
phage products for human use, including preparations 
targeted against staphylococci, streptococci, E. 
coli, and other bacterial pathogens 
 were used to treat various infections, including 
abscesses, suppurating wounds, vaginitis, acute and 
chronic infections of the upper respiratory tract, and 
mastoid infections 
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Medical Uses  
 phages have also been used to treat anthrax, enteritis 
caused by Campylobacter species, Clostridium 
difficile gastrointestinal infections, gas gangrene, 
meningitis caused by Haemophilus influenzae, lung 
infections caused by Klebsiella 
pneumoniae, tuberculosis, gonorrhea, opportunistic 
infections of the lung caused by Proteus organisms, 
purulent infections related to Pseudomonas 
aeruginosa colonizationin burn patients, typhoid fever, 
and bacterial dysentery caused by Shigella species 
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Comparison to antibiotics 
 
 Though phage 
therapy aims to do 
the same thing as 
antibiotics in treating 
bacterial infections, 
they have different 
mechanisms and 
therefore different 
associated 
advantages and 
disadvantages 
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Advantages 
o One advantage of phage therapy is that phages 
cannot grow without their target bacteria 
o Another advantage is they would be easy to 
administer orally, intravenously, or topically 
o Phages are also more host-specific than antibiotics 
o Phages also work quickly. One study of mice infected 
with Vancomycin-resistant Enterococcus 
faecium found that if phage was injected 45 minutes 
after infection, 100% of the mice were saved 
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Advantages 
o The specificity of phages makes them less toxic than 
some antibiotics 
o Antibiotics also kill many of the bacteria that normally 
live on the human body (normal flora) 
o phages are highly specific they will not harm our cells            
or the normal flora, which allows us to use them in 
much higher concentrations  
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Advantages 
 phages are viruses they are readily cleared out of our 
bodies by our immune system 
o This prevents them from accumulating in our bodies 
and possibly causing any long lasting toxicity, making 
phages even less toxic to our cells 
o This also presents the problem that phages can be 
prevented from doing their job by being cleared out 
by our immune system 
o This is why the majority of phage cocktails are applied 
directly to wounds so they won’t enter the blood 
stream and activate the immune system  
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Advantages 
 Some bacteriophages synthesize enzymes that allow 
the breakdown of these biofilms so that the interior 
cells can be reached and lysed 
 Bacterial resistance to phages is also less of a concern 
than resistance to antibiotics 
o Even if resistance develops to a bacteriophage, 
finding a phage that will still work against that 
bacteria would only take a couple of days 
 Another major advantage is that bacteriophages are 
cheap to produce and the years of experimentation 
in Russia and Georgia have shown almost no side 
effects at all  
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Disadvantages 
 
 For example, though they would be easy to administer 
orally, this may lead to a need to neutralize the 
stomach acid before ingesting in order to minimize 
damage to the phage or to the delivery bacteria, 
which may not be able to survive at such a low pH 
 For the intravenous application of bacteriophages, 
they may be cleared by the human immune system 
which would recognize them as foreign and a possible 
threat 
 The phage would also need to be highly purified so 
that there is no dangerous contaminant or toxin going 
into the patient's circulatory system 
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Disadvantages 
 The fact that bacteriophages are so strongly specified 
for their bacterial target, though in some ways an 
advantage, can also serve as a disadvantage 
o this is because the exact bacteria must be diagnosed 
in order to use the right kind of phage. Antibiotics, on 
the other hand, affect a wider range of bacteria, so 
an exact diagnosis is not essential 
By:Peyman Hosseini / Dr.M.Aslanimehr 
42 
Comparison to antibiotics 
Bacteriophages Antibiotics Comments 
Very specific (i.e., usually affect only 
the targeted bacterial species); 
therefore, dysbiosis and chances of 
developing secondary infections are 
avoided  
Antibiotics target both pathogenic 
microorganisms and normal microflora. 
This affects the microbial balance in 
the patient, which may lead to serious 
secondary infections. 
High specificity may be considered to 
be a disadvantage of phages because 
the disease-causing bacterium must 
be identified before phage therapy 
can be successfully initiated. 
Antibiotics have a higher probability of 
being effective than phages when the 
identity of the etiologic agent has not 
been determined. 
Replicate at the site of infection and 
are thus available where they are 
most needed 
They are metabolized and 
eliminated from the body and do not 
necessarily concentrate at the site of 
infection. 
The "exponential growth" of phages 
at the site of infection may require 
less frequent phage administration in 
order to achieve the optimal 
therapeutic effect. 
No serious side effects have been 
described. 
Multiple side effects, including 
intestinal disorders, allergies, and 
secondary infections (e.g., yeast 
infections) have been reported 
A few minor side effects reported for 
therapeutic phages may have been 
due to the liberation of endotoxins 
from bacteria lysed in vivo by the 
phages. Such effects also may be 
observed when antibiotics are used 
Phage-resistant bacteria remain 
susceptible to other phages having a 
similar target range 
Resistance to antibiotics is not limited 
to targeted bacteria 
Because of their more broad-
spectrum activity, antibiotics select 
for many resistant bacterial species, 
not just for resistant mutants of the 
targeted bacteria 
Selecting new phages (e.g., against 
phage-resistant bacteria) is a 
relatively rapid process that can 
frequently be accomplished in days 
or weeks. 
Developing a new antibiotic (e.g., 
against antibiotic-resistant bacteria) 
is a time-consuming process and 
may take several years 
Evolutionary arguments support the 
idea that active phages can be 
selected against every antibiotic-
resistant or phage-resistant 
bacterium by the ever-ongoing 
process of natural selection 
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Conclusion 
 Bacterial resistance to antibiotics is a growing threat in 
our world. Though early studies of phage therapy did 
not produce consistently favorable results, there is 
reason to believe that with the enhanced 
understanding that we have of viral biology it is likely 
that bacteriophages can be a helpful therapeutic 
tool. Though many believe that phages will not 
replace antibiotics right away or maybe ever, there is 
definite potential for their use in conjunction with 
antibiotics 
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